Blood thinner pellets tested in kids with clots
NCT ID NCT05966740
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at the safety and effectiveness of Pradaxa oral pellets in children aged 3 months to 12 years who had blood clots (venous thromboembolism). The goal was to see how often bleeding or new clots occurred in real-world use. Only 5 children were enrolled before the study was terminated, so the findings are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pradaxa (dabigatran etexilate) oral pellets
What this could lead to
If successful, this study could provide real-world evidence that Pradaxa pellets are safe and effective for treating blood clots in young children.
What could go wrong
The study was terminated early with only 5 participants, so results are very limited. As an observational study, it cannot prove cause and effect.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VENOUS THROMBOEMBOLISM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cincinnati Children's Hospital
Cincinnati, Ohio, 45229, United States
-
Dayton Children's Hospital
Dayton, Ohio, 45404, United States
-
Dell Children's Ascension
Austin, Texas, 78723, United States
-
Indiana Hemophilia & Thrombrosis Center
Indianapolis, Indiana, 46260, United States
-
Johns Hopkins All Children's Hospital
St. Petersburg, Florida, 33701, United States
-
MUSC (Medical university of South Carolina)
Charleston, South Carolina, 29425, United States
-
Rady Children's Hospital
San Diego, California, 92123, United States
-
University of California, San Diego
La Jolla, California, 92093, United States
-
Vanderbilt University
Nashville, Tennessee, 37232, United States
-
Yale University School of Medicine
New Haven, Connecticut, 06519, United States